_edited.png)
RISK CONCERN
Investment Strategy, Risk Analysis, and Insights by Chartered Professionals
Angiodynamics, Inc. (XNAS:ANGO) In-Depth Stock/Fundamental/Options Analysis Today
Primary Facts
ANGO
Name:
ANGIODYNAMICS, INC. (XNAS:ANGO)
Sector:
- 9925.00K
Industry:
Medical Instruments & Supplies
CEO:
Mr. James Clemmer
Total Employees:
760
Our Technological Advancement Rating
Our Rating:
D
Technological advancement compared to industry is -828.52% lower
ANALYSIS OF ALL CRITICAL FACTORS & RISKS RELATED TO THE STOCK & FUNDAMENTAL/LONG-TERM ANALYSIS OF ANGIODYNAMICS, INC.(ANGO) AS PER DATA ANALYSIS OF LAST 3 YEARS AND COMPARISON WITH COMPETITORS/PEERS, AND MEDICAL INSTRUMENTS & SUPPLIES INDUSTRY. DATE: 07/09/2022
Primary Targets/Price Insights
Previous Close ($) :
20.85
One Month Price Target:
$20.96
Six Month Price Target :
$21.48
Likely Price in One Year's Time:
Ticker:
$22.12
Likely Trading Range Today Under (Normal Volatility)
$20.75
Price Upper limit ($) :
$20.99
Price Lower limit ($) :
Crash Risk Prep/Key Price Levels (High Volatility/Risk)
Price, as per data analysis, isn't likely to fall below:
Today:
$19.47
This week:
$17.77
This month :
$14.69
Other Primary facts
Market Cap:
821.49M
Market Cap Classification:
Small Cap
Number of Shares
IPO Date:
38.97M
Best/Worst Daily Performance (Last 3+ Years)
Highest Daily Appreciation:
19.4%
-15.77%
Worst Daily Decline:
Our Options Trading Entry Points
Iron Condor entry points for options expiring in 1 week's time
Low risk (<2%) entry points
Buy Call:
Sell Call:
Buy Put:
Sell Put:
$27.24
$24.29
$14.46
$17.41
Medium risk (<10%) entry points
Buy Call
Sell Call
$23.33
Buy Put:
Sell Put:
$22.70
$18.36
$19.00
These entry points can be used for other strategies, such as butterflies, straddles, etc.
Risk-Adjusted returns (Sharpe Ratio) of
ANGO
Sharpe Ratio:
2.67%
Comparison:
ANGO, is amongst the top 40% stocks with highest risk-adjusted returns
Sharpe ratio is 67.04% higher than the industry
& ratio is 17.35% higher than the market/S&P 500 average
Average Returns/Yield of
ANGO
Daily returns:
0.10%
Weekly returns:
0.48%
Monthly returns:
1.92%
Yearly returns:
14.68%
Comparison of returns:
Average annual returns/yield (last 3 years) is 57.16% above industry average
Classification:
ANGO, is amongst the top 40% highest yielding stocks in terms of daily returns
Results of T-Test of Returns:
0.6
Statistical test of Returns:
ANGO has yielded returns statistically similar to the market
Volatility (measured by Standard Deviation)
Daily Volatility:
3.26%
Weekly Volatility:
7.30%
Monthly Volatility:
14.60%
Yearly Volatility:
50.56%
Volitlilty of last five days (Measured by Standard Deviation)
Average Volatility of this Week:
2.62%
Volatility in last five trading days has been -19.75% below long-term volatility
Value at Risk Analysis (VaR)
Daily VaR:
-6.61%
Weekly VaR:
-14.77%
Monthly VaR:
-29.55%
How Much Can the price of
ANGO
Decline in a Recession?
Likely price decline in a recession:
Base case (decline):
-25%
Worst case (decline):
>85%
This translates to price declining to:
$15.63
This translates to price declining to:
$3.13
Severe Crash Probability
Risk of crash in next 6/12 months: Very high (>70%)
What is Value at Risk (VaR)?
Risk Fundamentals
ANGO is a 108.54% riskier investment compared to the market/S&P 500 & is 78.65% riskier than Nasdaq (IXIC)
Risk (measured by volatility) is 12.42% above industry average
Overall, it is amongst the top 50% most risky stocks
Beta Examination of
ANGO
Beta in relation to market/S&P 500--0.91
Expected beta in 1 year's time:
0.656
Expected beta in 3 year's time:
0.928
Unlevered (debt free) Beta:
0.862
Beta in relation to Nasdaq (XNAS):
0.552
Beta in relation to all global stocks::
0.774
Beta Comparison & Analysis
Beta of competitors/peers::
1.209
Beta is -25.11% lower than peers
Average Industry Beta:
0.989
Beta is -8.46% below industry average
Sustainable Growth Rate Analysis
Sustainable growth rate for this stock/firm:
-
-
Alpha provided | Alpha Analysis
Alpha provided:
0.137
Alpha is 188.51% above industry average alpha yield
Alpha is 873% higher than market/& is unsustainably high
Analysis of Cost of Capital of
ANGO
Equity cost of capital:
0.094
Equity cost of capital is -5.78% below industry mean WACC
Unlevered (without debt) cost of capital:
8.90%
Before-tax cost of debt:
2.75%
After-tax cost of debt:
2.17%
Overall debt rating:
High AA grade (second highest grade)
Weighted average cost of capital (WACC):
2.17%
WACC is 3.52% above industry mean WACC
Key Per-Share Metrics & Analysis
Revenue per share:
$7.85
Revenue growth rate per share of (3Y):
1.86
Annual revenue growth rate is -153.18% below industry average
EPS:
-$1.03
Expected Annual growth rate of EPS (3Y):
0.00%
-
Free cash flow (FCF) per share:
-
-
-
Debt per share
$0.64
EBITDA per share
-$0.42
Valuation Analysis Today of
ANGO
P/E Ratio:
8.34
P/E Ratio of Competitors/Peers:
41.62
P/E ratio is -79.97% lower than main peers & is -83.29% lower than the industry
-
ANGO is -140.57% undervalued if valued using industry average P/E ratio
-
-
P/S (Price to Sales ratio):
2.65
Price to sales ratio is -64.20% below the industry mean
P/B (Price to book value ratio):
1.86
-
Price to free cash flow ratio is 85.43% higher than the industry
Net income growth rate (3Y):
-3312.50%
Net income growth rate is 3034.62% higher than the average industry net income growth rate
Dividend Analysis
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Dividend History:
--$0.00
--$0.00
--$0.00
--$0.00
--$0.00
--$0.00
-
In-depth Debt & Leverage Analysis
Debt to equity ratio:
5.73%
Net debt to equity ratio:
-2.40%
Debt to assets ratio:
4.50%
Net debt to assets ratio:
-1.88%
Debt-to-asset ratio is -87.47% below industry average
Ability to repay debt:
Interest coverage ratio:
-23.65
Interest coverage ratio is -133.34% less than industry average
Looking forward:
Debt growth rate:
-50.00%
Annual debt growth is -145% lower than industry average debt growth rate
Debt repayment rate in last quarter: 0.00%
Analysis of Key Statistics
Correlation of price movement with the market:
0.352
Statistical significance of correlation:
ANGO has a statistically significant correlation with the market
Average Correlation of the industry with the market:
0.505
Stock price is -30.27% less correlated with the market compared to the industry average correlation
R Squared (percentage of price movement explained by movement of the market):
0.505
Correlation of price movement with Nasdaq (^IXIC):
-0.009
Covariance of price movement with the market:
-0.016
Kurtosis
5.174
Returns have moderate fat-tails (leptokurtic), i.e., returns considerably higher or lower than the mean returns are more probable, compared to assets with normally distributed returns
Skewness of returns:
0.373
Returns are, approximately, symmetrical
Fundamental Analysis & Dupont Analysis of
ANGO
Gross Profit Margin Ratio:
211%
Operating Profit Margin Ratio:
-14.27%
Operating profit margin is -206.57% lower than the industry
Net Profit Margin Ratio:
211%
Effective Tax Rate:
12.00%
Effective tax rate is -63.50% lower than the industry
Dupont Method
Net Profit Margin
Return on Equity Ratio (ROE):
×
ROA
=
×
-9.12%
Return on equity (ROE) is -80.00% lower than the industry
Financial Leverage
Asset Turnover Ratio (ROA):
-7.15%
Return on assets (ROA) is -199.86% lower than the industry
Financial Leverage:
1.0x
Current Ratio:
2.52
Current ratio is -30.97% below industry average
Cash Conversion Cycle (days):
14.3
Cash conversion cycle is -72.92% below industry average
The remaining useful life of property plant & equipment is: 1.8 years
Stock based compensation to net income ratio:
-6.11%
In-depth Efficiency Analysis
Revenue generated per employee:
402.7K
Each employee generates 14% more revenue than industry average revenue per employee
EBITDA generated per employee:
- 21.4K
Each employee generates -119% less EBITDA than industry average revenue per employee
Profit generated per employee:
- 52.3K
Each employee generates -167% less net income/profit than industry average revenue per employee
Free cash flow (FCF) generated per employee:
- 13.1K
Each employee generates 127% more free cash flow than industry average revenue per employee
Assets/Capital per employee
558.5K
Each employee generates 127% more free cash flow than industry average revenue per employee
Research & Development (R&D) Analysis
Research & development (R&D) investment growth rate-- 5.04%
Growth rate in R&D investment/expenditure is 1846.24% higher than the industry
Competitors/Peer firms of
ANGO
BLACK DIAMOND THERAPEUTICS, INC. (XNAS:BDTX)
NKARTA, INC. (XNAS:NKTX)
NATUS MEDICAL INCORPORATED (XNAS:NTUS)
Trean Insurance Group Inc (XNAS:TIG)
PASSAGE BIO, INC. (XNAS:PASG)
CURIS, INC. (XNAS:CRIS)
So-Young International Inc. (XNAS:SY)
IKENA ONCOLOGY, INC. (XNAS:IKNA)
Connect Biopharma Holdings Ltd (XNAS:CNTB)
Current Analyst Ratings
Strong buy�0%
Buy�4%
Hold�17%
Sell�0%
Strong sell�0%
Overall analyst sentiment is: Hold
Income Statement
Period:
TTM
Date:
2/28/22
Revenue:
306.06M
Cost of Revenue:
Gross Profit:
R&D Expense
General & Admin Expenses:
Selling, General & Admin Expenses
Sales and Marketing Expenses
Other Expenses :
Operating Expenses :
Cost & Expenses :
Interest Income:
Interest Expenses:
Depreciation & Amortization:
EBITDA:
Operating Income:
Other Income Expenses:
Income Before Tax:
Income Tax Expense:
Net Income:
Balance Sheet
Date:
Calendar Year:
Period:
Cash & Cash Equivalents:
Short Term Investments:
Cash & Short Term Investments:
Net Receivables:
Inventory:
Other Current Assets:
Total Current Assets:
PP&E:
Goodwill:
Intangible Assets:
Long Term Investments:
Tax Assets:
Other Non-Current Assets:
Total Non-Current Assets:
Other Assets:
Total Assets:
Accounts Payable:
Short Term Debt:
Tax Payables:
Deferred Revenue:
Other Current Liabilities:
Total Current Liabilities:
Long Term Debt:
Other Non-Current Liabilities:
Total Non Current Liabilities:
Other Liabilities:
Total Liabilities:
Common Stock:
Retained Earnings:
Accumulated Other Comprehensive Loss:
Other Total Stockholders' Equity:
Total Stockholders' Equity:
Total Liabilities and Stockholders' Equity:
Total Investments:
Total Debt:
Net Debt:
144.47M
161.60M
31.98M
36.48M
128.77M
92.29M
18.90M
179.65M
-
688.00K
28.21M
- 16273.00K
- 43661.00K
- 39749.00K
- 45167.00K
- 5418.00K
- 39749.00K
Statement of Cash Flow
Date:
Period:
7.00M
Differed Income Tax :
- 1690.00K
Stock Based Compensation :
2.43M
Change in Working Capital :
- 10405.00K
Accounts Receivables:
- 36.00K
Other Working Capital:
79.22M
Other Non-Cash Items:
737.00K
Net Cash Provided by Operating Activities:
- 8904.00K
Investments in PP&E:
- 1021.00K
Net Acquisitions:
- 3600.00K
Purchases of Investments:
-
Sales/Maturities of Investments:
Other Investing Activities:
Net Cash Used for Investing Activities:
Debt Repayment:
Common Stock Issued:
Common Stock Repurchased:
Dividend Paid:
Other Financing Activities:
Net Cash Used Provided by Financing Activities:
Effect of FOREX on Changes in Cash:
Net Changes in Cash:
Cash at End of Period:
Cash at Beginning of Period:
Operating Cash Flow:
Capital Expenditure:
Free Cash Flow (FCF):
8/31/21
2022
Q1
35.47M
-
35.47M
35.42M
49.31M
11.13M
131.32M
41.13M
201.49M
168.89M
-
-
12.93M
424.44M
-
555.76M
22.69M
-
819.00K
-
29.41M
52.10M
25.00M
24.32M
67.72M
-
119.81M
379.00K
- 138838.00K
3.7M
570.67M
August 31, 2021 at 6:00:00 AM
324.11M
435.95M
555.76M
-
25.00M
- 10472.0K
-
- 4471.00K
- 9092.00K
-
-
-
-
5.45M
5.45M
- 139.00K
- 12689.00K
35.47M
48.16M
- 8904.00K
- 1021.00K
- 9925.00K
Our Proprietary Portfolio Rating
Our Rating:
D
Price Forecast/Expected Price in Next 5 Years of
ANGO
2023
2024
2025
2026
2027
$22.23
$6.88
$7.30
$7.75
$8.22